Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SPFPL PHARMONOR : revenue, balance sheet and financial ratios

SPFPL PHARMONOR is a French company founded 6 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in SAINT-AVOLD (57500), this company of category PME shows in 2020 a net income positive of 22 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SPFPL PHARMONOR (SIREN 880623970)
Indicator 2020 2019
Revenue N/C N/C
Net income 21 734 € -1 401 €
EBITDA -6 549 € -722 €
Net margin N/C N/C

Revenue and income statement

In 2020, SPFPL PHARMONOR generates positive net income of 22 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

EBITDA (2020) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-6 549 €

EBIT (2020) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-6 549 €

Net income (2020) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

21 734 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 1682%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 6%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 16.5 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.

Debt ratio (2020) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

1681.812%

Financial autonomy (2020) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

5.612%

Repayment capacity (2020) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

16.508

Solvency indicators evolution
SPFPL PHARMONOR

Sector positioning

Debt ratio
1681.81 2020
2019
2020
Q1: 0.01
Med: 10.43
Q3: 82.59
Average +60 pts over 2 years

In 2020, the debt ratio of SPFPL PHARMONOR (1681.81) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
5.61% 2020
2019
2020
Q1: 16.33%
Med: 62.48%
Q3: 90.92%
Average

In 2020, the financial autonomy of SPFPL PHARMONOR (5.6%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Repayment capacity
16.51 years 2020
2019
2020
Q1: -0.03 years
Med: 0.01 years
Q3: 3.79 years
Average +50 pts over 2 years

In 2020, the repayment capacity of SPFPL PHARMONOR (16.51) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

Interest coverage (2020) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-50.328

Liquidity indicators evolution
SPFPL PHARMONOR

Sector positioning

Liquidity ratio
333.82 2019
2019
Q1: 101.23
Med: 462.1
Q3: 2664.44
Average

In 2019, the liquidity ratio of SPFPL PHARMONOR (333.82) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
-50.33x 2020
2019
2020
Q1: -63.5x
Med: 0.0x
Q3: 0.0x
Average +5 pts over 2 years

In 2020, the interest coverage of SPFPL PHARMONOR (-50.3x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Positioning of SPFPL PHARMONOR in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (25 transactions). This range of 146 523€ to 276 381€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2020
Indicative
146k€ 225k€ 276k€
225 219 € Range: 146 523€ - 276 381€
NAF 5 année 2020
How is this estimate calculated?

This estimate is based on the analysis of 25 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare SPFPL PHARMONOR with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about SPFPL PHARMONOR

What is the revenue of SPFPL PHARMONOR ?

The revenue of SPFPL PHARMONOR is not publicly disclosed (confidential accounts filed with INPI).

Is SPFPL PHARMONOR profitable?

Yes, SPFPL PHARMONOR generated a net profit of 22 k€ in 2020.

Where is the headquarters of SPFPL PHARMONOR ?

The headquarters of SPFPL PHARMONOR is located in SAINT-AVOLD (57500), in the department Moselle.

Where to find the tax return of SPFPL PHARMONOR ?

The tax return of SPFPL PHARMONOR is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SPFPL PHARMONOR operate?

SPFPL PHARMONOR operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.